Novo Nordisk Pharmatech invites you to visit its booth (booth #12) at the 7th Annual Biologics Manufacturing Korea in Seoul, Korea.

The event will take place from 29 May to 31 May at the Hotel Novotel Ambassador Seoul Gangnam. Organise a visit to discover more about the firm’s recombinant insulin for innovative biologics.

Novo Nordisk Pharmatech remains one of the leading worldwide suppliers of recombinant insulin. Its recombinant insulin is a key component in serum-free growth media for mammalian cells and is approved by regulatory bodies worldwide, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It products are also manufactured to current good manufacturing practice (cGMP) standards.

Novo Nordisk Pharma guarantees:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

The company delivers a proven record of product purity, reliability and consistency, and can even tailor high-quality products for future therapies

Chinese hamster ovary (CHO) cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media from serum-containing to serum-free and further on to chemically defined media.

UAB in collaboration with Novo Nordisk Pharmatech has shown that the addition of animal origin-free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density.

In addition, insulin has been proven to aid in the expression of difficult-to-express proteins.

Please stop by Novo Nordisk Pharmatech’s booth to talk about how insulin could play an important role in your upstream process and for the chance to win an Amazon Kindle.